EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Defects in EGF are the cause of hypomagnesemia type 4 (HOMG4); also known as renal hypomagnesemia normocalciuric. HOMG4 is a disorder characterized by massive renal hypomagnesemia and normal levels of serum calcium and calcium excretion. Clinical features include seizures, mild-to mederate psychomotor retardation, and brisk tendon reflexes. 2 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: Membrane protein, integral; Ligand, receptor tyrosine kinase; Hormone
Cellular Component: extracellular space; integral to membrane; lysosomal membrane; membrane; plasma membrane; receptor complex
Molecular Function: calcium ion binding; epidermal growth factor receptor binding; growth factor activity; protein binding; Wnt receptor activity; Wnt-protein binding
Biological Process: activation of MAPK activity; activation of MAPKK activity; angiogenesis; branching morphogenesis of a tube; epidermal growth factor receptor signaling pathway; negative regulation of secretion; peptidyl-tyrosine phosphorylation; positive regulation of cell proliferation; positive regulation of DNA binding; positive regulation of epidermal growth factor receptor activity; positive regulation of fibroblast proliferation; positive regulation of granule cell precursor proliferation; positive regulation of MAP kinase activity; positive regulation of mitosis; positive regulation of peptidyl-tyrosine phosphorylation; positive regulation of phosphorylation; positive regulation of transcription, DNA-dependent; regulation of peptidyl-tyrosine phosphorylation; regulation of protein secretion; regulation of protein transport; STAT protein nuclear translocation; Wnt receptor signaling pathway through beta-catenin
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.